Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2006 3
2007 3
2008 5
2009 9
2010 4
2011 7
2012 5
2013 3
2014 5
2015 9
2016 11
2017 8
2018 8
2019 6
2020 3
2021 8
2022 7
2023 11
2024 14
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Addendum „Antivirale Therapie der chronischen Hepatitis-D-Virusinfektion“ zur S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).
Sandmann L, Berg T, Deterding K, Fischer N, Hinrichsen H, Petersen J, Tacke F, Cornberg M; Collaborators. Sandmann L, et al. Among authors: deterding k. Z Gastroenterol. 2023 Dec;61(12):1635-1653. doi: 10.1055/a-2181-3046. Epub 2023 Dec 11. Z Gastroenterol. 2023. PMID: 38081179 Free article. German. No abstract available.
[Acute viral hepatitis].
Deterding K. Deterding K. Dtsch Med Wochenschr. 2024 Aug;149(16):941-947. doi: 10.1055/a-2057-1761. Epub 2024 Aug 2. Dtsch Med Wochenschr. 2024. PMID: 39094598 Review. German.
EASL position paper on clinical follow-up after HCV cure.
Reiberger T, Lens S, Cabibbo G, Nahon P, Zignego AL, Deterding K, Elsharkawy AM, Forns X. Reiberger T, et al. Among authors: deterding k. J Hepatol. 2024 Aug;81(2):326-344. doi: 10.1016/j.jhep.2024.04.007. Epub 2024 Jun 6. J Hepatol. 2024. PMID: 38845253
Incidence and Clinical Significance of Recompensation After HCV Cure.
Semmler G, Lens S, Hidalgo Á, Alonso López S, Perez-Perez M, Dajti E, Kabelitz M, Zanaga P, Hofer BS, Marino Z, Manzano ML, Payeras I, Pons M, Bruni A, Zanetto A, Burghart L, Ecker D, Simonis L, Pocurull A, Fritz L, Collazos C, Neumayer D, Balcar L, Jachs M, Reiberger T, Russo FP, Maasoumy B, Genesca J, Bañares R, Forns X, Fernandez I, Mandorfer M; HCV Recompensation Study Group. Semmler G, et al. Clin Gastroenterol Hepatol. 2025 May 14:S1542-3565(25)00414-8. doi: 10.1016/j.cgh.2025.04.026. Online ahead of print. Clin Gastroenterol Hepatol. 2025. PMID: 40378989 Free article.
Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial.
Ripoll C, Platzer S, Franken P, Aschenbach R, Wienke A, Schuhmacher U, Teichgräber U, Stallmach A, Steighardt J, Zipprich A; Liver-HERO Study Group. Ripoll C, et al. Trials. 2023 Apr 5;24(1):258. doi: 10.1186/s13063-023-07261-9. Trials. 2023. PMID: 37020315 Free PMC article. Clinical Trial.
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
Dietz J, Graf C, Berg CP, Port K, Deterding K, Buggisch P, Peiffer KH, Vermehren J, Dultz G, Geier A, Reiter FP, Bruns T, Schattenberg JM, Durmashkina E, Gustot T, Moreno C, Trauth J, Discher T, Fischer J, Berg T, Kremer AE, Müllhaupt B, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Among authors: deterding k. JHEP Rep. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072. eCollection 2024 Jul. JHEP Rep. 2024. PMID: 39006503 Free PMC article.
124 results